AKBA: Akebia Therapeutics, Inc. Company Cash Volume

Official company branding of Akebia Corp (AKBA)

The cash position of Akebia Therapeutics (AKBA) demonstrates market expectations, where the value of 0.16 reflects this status. Partnerships with global nephrology behemoths support this growth. However, business resilience relies on FDA approvals and patent protection. Active sales of Vadadustat in the US are currently driving momentum, while expansion into the European market is expected.

AKBA - Akebia Corp Company Cash Volume over the range 07/04/2022 - 11/22/2026

Comprehensive metric breakdowns and analytics for Akebia Therapeutics, Inc. (AKBA)

Fundamental valuation:Akebia Therapeutics Inc
Product sample of akebia.com

Akebia Therapeutics (AKBA) expansion into the market for anemia treatments in CKD requires significant resources to scale its dialysis center network. An analysis of cash on hand captures the volume of immediate liquidity, allowing for an assessment of the balance between financial resilience against cash flow gaps and capital efficiency, which is critical for minimizing opportunity costs within the portfolio.